Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Climb Bio, Inc.

NASDAQ: CLYM · Life Sciences · 4 alerts · CIK 1768446

Share price
$9.94Close, Nov 16
Market cap
$584M
Shares outstanding
58.74MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Climb Bio, Inc. filings on SEC EDGAR ↗

6:24 AM ET 8-K
Clinical Trial Data

Climb Bio Clinical Trial Data

Climb Bio announced initial Phase 2 data from its PrisMN trial evaluating budoprutug in patients with primary membranous nephropathy (pMN), showing a 70% mean reduction in PLA2R antibody levels at Week 12 in the 200 mg cohort. Initial data from the 600 mg cohort indicated deeper B-cell depletion and greater drug exposure, supporting the ongoing evaluation of higher doses. The company also reported a case study in minimal change disease (MCD) where a patient achieved a three-year steroid-free remission following treatment.

5:27 PM ET 8-K
Clinical Trial Data

Climb Bio Clinical Trial Data

Climb Bio and Mabworks announced additional Phase 1 clinical data for CLYM116, an anti-APRIL monoclonal antibody for IgA nephropathy, demonstrating deep and durable APRIL suppression through 12 weeks. The data showed a 33-day half-life and a 70% reduction in Gd-IgA1 at 12 weeks, supporting a potential every-12-week dosing regimen. The company remains on track to report initial Phase 2 data in the first half of 2027 and plans to initiate a global Phase 3 trial in 2027.

Counterparty
Beijing Mabworks Biotech Co., Ltd.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.